A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients.

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BCG bladder cancer vaccine-Verity Pharmaceuticals (Primary) ; BCG vaccine
Indications Bladder cancer; Carcinoma
Focus Registrational; Therapeutic Use
Acronyms EVER
Sponsors Verity Pharmaceuticals

Most Recent Events

11 Oct 2022 Planned initiation date changed from 1 Jun 2022 to 1 Jan 2023.
07 Apr 2022 Planned End Date changed from 30 Aug 2026 to 31 Jan 2026.
07 Apr 2022 Planned primary completion date changed from 30 Jul 2025 to 30 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight